1
|
Gray ME, Zielinski KM, Xu F, Elder KK, McKay SJ, Ojo VT, Benjamin SR, Yaseen AA, Brooks TA, Tumey LN. A comparison of the activity, lysosomal stability, and efficacy of legumain-cleavable and cathepsin cleavable ADC linkers. Xenobiotica 2024:1-13. [PMID: 38738708 DOI: 10.1080/00498254.2024.2352051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2024] [Accepted: 05/02/2024] [Indexed: 05/14/2024]
Abstract
1. Over the past two decades antibody-drug conjugates (ADCs) have emerged as a highly effective drug delivery technology. ADCs utilize a monoclonal antibody, a chemical linker, and a therapeutic payload to selectively deliver highly potent pharmaceutical agents to specific cell types.2. Challenges such as premature linker cleavage and clearance due to linker hydrophobicity have adversely impacted the stability and safety of ADCs. While there are various solutions to these challenges, our team has focused on replacement of hydrophobic ValCit linkers (cleaved by CatB) with Asn-containing linkers that are cleaved by lysosomal legumain.3. Legumain is abundantly present in lysosomes and is known to play a role in tumor microenvironment dynamics. Herein, we directly compare the lysosomal cleavage, cytotoxicity, plasma stability, and efficacy of a traditional cathepsin cleavable ADC to a matched Asn-containing legumain-cleavable ADC.4. We demonstrate that Asn-containing linker sequences are specifically cleaved by lysosomal legumain and that Asn-linked MMAE ADCs are broadly active against a variety of tumors, even those with low legumain expression. Finally, we show that AsnAsn-linked ADCs exhibit comparable or improved efficacy to traditional ValCit-linked ADCs. Our study paves the way for replacement of the traditional ValCit linker technology with more hydrophilic Asn-containing peptide linker sequences.
Collapse
Affiliation(s)
- Meghan E Gray
- Binghamton University, School of Pharmacy and Pharmaceutical Sciences, PO Box 6000, Binghamton NY 13902-6000, USA
| | - Karina M Zielinski
- Binghamton University, School of Pharmacy and Pharmaceutical Sciences, PO Box 6000, Binghamton NY 13902-6000, USA
| | - Fanny Xu
- Binghamton University, School of Pharmacy and Pharmaceutical Sciences, PO Box 6000, Binghamton NY 13902-6000, USA
| | - Kayla K Elder
- Binghamton University, School of Pharmacy and Pharmaceutical Sciences, PO Box 6000, Binghamton NY 13902-6000, USA
| | - Steven J McKay
- Binghamton University, School of Pharmacy and Pharmaceutical Sciences, PO Box 6000, Binghamton NY 13902-6000, USA
| | - Victor T Ojo
- Binghamton University, School of Pharmacy and Pharmaceutical Sciences, PO Box 6000, Binghamton NY 13902-6000, USA
| | - Samantha R Benjamin
- Binghamton University, School of Pharmacy and Pharmaceutical Sciences, PO Box 6000, Binghamton NY 13902-6000, USA
| | - Aiman A Yaseen
- Binghamton University, School of Pharmacy and Pharmaceutical Sciences, PO Box 6000, Binghamton NY 13902-6000, USA
| | - Tracy A Brooks
- Binghamton University, School of Pharmacy and Pharmaceutical Sciences, PO Box 6000, Binghamton NY 13902-6000, USA
| | - L Nathan Tumey
- Binghamton University, School of Pharmacy and Pharmaceutical Sciences, PO Box 6000, Binghamton NY 13902-6000, USA
| |
Collapse
|
2
|
Howe JM, Fang S, Watts KA, Xu F, Benjamin SR, Tumey LN. ValCitGlyPro-dexamethasone antibody conjugates selectively suppress the activation of human monocytes. RSC Med Chem 2023; 14:2348-2357. [PMID: 37974960 PMCID: PMC10650436 DOI: 10.1039/d3md00336a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2023] [Accepted: 09/18/2023] [Indexed: 11/19/2023] Open
Abstract
Glucocorticoids (GCs) are effective in treating autoimmune and inflammatory disorders but come with significant side effects, many of which are mediated by non-immunological cells. Therefore, there is rapidly growing interest in using antibody drug conjugate (ADC) technology to deliver GCs specifically to immune cells, thereby minimizing off-target side effects. Herein, we report the study of anti-CD11a, anti-CD38, and anti-TNFα ADCs to deliver dexamethasone to monocytes. We found that anti-CD11a and anti-CD38 were rapidly internalized by monocytes, while uptake of anti-TNFα depended on pre-activation with LPS. Using these antibodies were attached to a novel linker system, ValCitGlyPro-Dex (VCGP-Dex), that efficiently released dexamethasone upon lysosomal catabolism. This linker relies on lysosomal cathepsins to cleave after the ValCit sequence, thereby releasing a GlyPro-Dex species that undergoes rapid self-immolation to form dexamethasone. The resulting monocyte-targeting ADCs bearing this linker payload effectively suppressed LPS-induced NFκB activation and cytokine release in both a monocytic cell line (THP1) and in human PBMCs. Anti-TNFα_VCGP-Dex and anti-CD38_VCGP-Dex were particularly effective, suppressing ∼60-80% of LPS-induced IL-6 release from PBMCs at 3-10 μg mL-1 concentrations. In contrast, the corresponding isotype control ADC (anti-RSV) and the corresponding naked antibodies (anti-CD38 and anti-TNFα) resulted in only modest suppression (0-30%) of LPS-induced IL-6. Taken together, these results provide further evidence of the ability of glucocorticoid-ADCs to selectively suppress immune responses, and highlight the potential of two targets (CD38 and TNFα) for the development of novel immune-suppressing ADCs.
Collapse
Affiliation(s)
- Justin M Howe
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University PO Box 6000 Binghamton NY 13902-6000 USA
| | - Siteng Fang
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University PO Box 6000 Binghamton NY 13902-6000 USA
| | - Kelsey A Watts
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University PO Box 6000 Binghamton NY 13902-6000 USA
| | - Fanny Xu
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University PO Box 6000 Binghamton NY 13902-6000 USA
| | - Samantha R Benjamin
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University PO Box 6000 Binghamton NY 13902-6000 USA
| | - L Nathan Tumey
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University PO Box 6000 Binghamton NY 13902-6000 USA
| |
Collapse
|
3
|
DeYoung EG, Howe JM, Fang S, Reddy MM, Handel JP, Gillen Miller JT, Wheeler DR, Tumey LN. Synthesis and Optimization of 1-Substituted Imidazo[4,5- c]quinoline TLR7 Agonists. ACS Med Chem Lett 2023; 14:1358-1368. [PMID: 37849530 PMCID: PMC10577892 DOI: 10.1021/acsmedchemlett.3c00260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2023] [Accepted: 09/06/2023] [Indexed: 10/19/2023] Open
Abstract
TLR7 agonists have significant therapeutic potential in a variety of oncology and autoimmune applications. We recently reported a potent TLR7 selective agonist 1 that could be delivered by antibody-drug conjugate (ADC) technology to elicit potent anticancer activity. Herein we report synthetic chemistry and structure-activity relationship studies to develop TLR7 agonists with improved potency for next-generation ADC efforts. We found that the addition of hydrophobic acyl tails to parent compound 1 generally resulted in retained or improved TLR7 agonist activity without sacrificing the permeability or the selectivity over TLR8. In contrast, the addition of a simple alkyl tail at the same position resulted in a dramatic loss in potency. Molecular modeling was performed to provide a rationale for this dramatic loss in potency. We ultimately identified compounds 17b, 16b, and 16d as highly potent TLR7 agonists that potently induced the activation of mouse macrophages and hPBMCs at low-nanomolar concentrations.
Collapse
Affiliation(s)
- Emma G. DeYoung
- Binghamton University School of Pharmacy
and Pharmaceutical Sciences, Johnson
City, New York 13790, United States
| | - Justin M. Howe
- Binghamton University School of Pharmacy
and Pharmaceutical Sciences, Johnson
City, New York 13790, United States
| | - Siteng Fang
- Binghamton University School of Pharmacy
and Pharmaceutical Sciences, Johnson
City, New York 13790, United States
| | - Mullapudi Mohan Reddy
- Binghamton University School of Pharmacy
and Pharmaceutical Sciences, Johnson
City, New York 13790, United States
| | - Jillian P. Handel
- Binghamton University School of Pharmacy
and Pharmaceutical Sciences, Johnson
City, New York 13790, United States
| | - Jared T. Gillen Miller
- Binghamton University School of Pharmacy
and Pharmaceutical Sciences, Johnson
City, New York 13790, United States
| | - Daniel R. Wheeler
- Binghamton University School of Pharmacy
and Pharmaceutical Sciences, Johnson
City, New York 13790, United States
| | - L. Nathan Tumey
- Binghamton University School of Pharmacy
and Pharmaceutical Sciences, Johnson
City, New York 13790, United States
| |
Collapse
|
4
|
Yuan Y, Olawode EO, Tumey LN, Lu F. Visualizing drug-induced lipid accumulation in lysosomes of live cancer cells with stimulated Raman imaging. Biomed Opt Express 2023; 14:2551-2564. [PMID: 37342714 PMCID: PMC10278636 DOI: 10.1364/boe.487527] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/10/2023] [Revised: 03/31/2023] [Accepted: 04/04/2023] [Indexed: 06/23/2023]
Abstract
The low pH of the lysosomal compartment often results in sequestration of chemotherapeutic agents that contain positively charged basic functional groups, leading to anti-cancer drug resistance. To visualize drug localization in lysosomes and its influence on lysosomal functions, we synthesize a group of drug-like compounds that contain both a basic functional group and a bisarylbutadiyne (BADY) group as a Raman probe. With quantitative stimulated Raman scattering (SRS) imaging, we validate that the synthesized lysosomotropic (LT) drug analogs show high lysosomal affinity, which can also serve as a photostable lysosome tracker. We find that long-term retention of the LT compounds in lysosomes leads to the increased amount and colocalization of both lipid droplets (LDs) and lysosomes in SKOV3 cells. With hyperspectral SRS imaging, further studies find that the LDs stuck in lysosomes are more saturated than the LDs staying out of the lysosomes, indicating impaired lysosomal lipid metabolism by the LT compounds. These results demonstrate that SRS imaging of the alkyne-based probes is a promising approach to characterizing the lysosomal sequestration of drugs and its influence on cell functions.
Collapse
Affiliation(s)
- Yuhao Yuan
- Department of Biomedical Engineering, Thomas J. Watson College of Engineering and Applied Science, Binghamton University, State University of New York, Binghamton, NY 13902, USA
- Current Address: Department of Electrical and Computer Engineering, Boston University, Boston, MA 02215, USA
| | - Emmanuel O. Olawode
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University, State University of New York, Binghamton, NY 13902, USA
- Current Address: College of Pharmacy, Larkin University, Miami, FL 33169, USA
| | - L. Nathan Tumey
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University, State University of New York, Binghamton, NY 13902, USA
| | - Fake Lu
- Department of Biomedical Engineering, Thomas J. Watson College of Engineering and Applied Science, Binghamton University, State University of New York, Binghamton, NY 13902, USA
| |
Collapse
|
5
|
Jackson CP, Fang S, Benjamin SR, Alayi T, Hathout Y, Gillen SM, Handel JP, Brems BM, Howe JM, Tumey LN. Evaluation of an ester-linked immunosuppressive payload: A case study in understanding the stability and cleavability of ester-containing ADC linkers. Bioorg Med Chem Lett 2022; 75:128953. [PMID: 36058468 PMCID: PMC10166636 DOI: 10.1016/j.bmcl.2022.128953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2022] [Revised: 07/28/2022] [Accepted: 08/21/2022] [Indexed: 11/29/2022]
Abstract
In spite of their value in prodrug applications, the use of esters in antibody-drug-conjugate (ADC) payloads and linkers has generally been avoided due to the ubiquitous and promiscuous nature of human esterases. ADCs generally have a long circulating half life (3-7 days) that makes them susceptible to esterase-mediated metabolism. Moreover, it is largely unclear whether lysosomal and cytosolic esterases cleave ester-containing linkers upon ADC internalization. Due to our interest in the targeted delivery of immune-modulators, our team has recently prepared a series of ester-linked dexamethasone ADCs. Herein, we report our studies of the functional activity of these ADCs, with a particular focus on their catabolism in various biological milieu. We found that esters are selectively but inefficiently cleaved upon cellular uptake, likely by cytosolic esterases. Lysosomal catabolism studies indicate that, in spite of the strong proteolytic activity, very little cleavage of ester-containing linkers occurs in the lysosome. However, ADCs bearing the ester-linked payloads are active in various immune-suppressive assays, suggesting that cytosolic cleavage is taking place. This was confirmed through LCMS quantitation of the payload following cell lysis. Finally, the stability of the ester linkage was evaluated in mouse and human plasma. We found, similar to other reports, there is a significant site-dependence on the cleavage. Esters attached at highly exposed sites, such as 443C, were rapidly cleaved in plasma while esters at more hindered sites, such at 334C, were not. Together, these results help to unravel the complexities of ester-incorporation into ADC linkers and pave a path forward for their utility in ADC applications.
Collapse
Affiliation(s)
- Courtney P Jackson
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University, P.O. Box 6000, Binghamton, NY 13902, United States
| | - Siteng Fang
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University, P.O. Box 6000, Binghamton, NY 13902, United States
| | - Samantha R Benjamin
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University, P.O. Box 6000, Binghamton, NY 13902, United States
| | - Tchilabalo Alayi
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University, P.O. Box 6000, Binghamton, NY 13902, United States
| | - Yetrib Hathout
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University, P.O. Box 6000, Binghamton, NY 13902, United States
| | - Sarah M Gillen
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University, P.O. Box 6000, Binghamton, NY 13902, United States
| | - Jillian P Handel
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University, P.O. Box 6000, Binghamton, NY 13902, United States
| | - Brittany M Brems
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University, P.O. Box 6000, Binghamton, NY 13902, United States
| | - Justin M Howe
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University, P.O. Box 6000, Binghamton, NY 13902, United States
| | - L Nathan Tumey
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University, P.O. Box 6000, Binghamton, NY 13902, United States.
| |
Collapse
|
6
|
Abstract
Traditional antibody-drug conjugate (ADC) technology has employed tumor-targeting antibodies to selectively deliver ultrapotent cytotoxins to tumor tissue. While this technology has been highly successful, resulting in the FDA approval of over 10 ADCs, the field continues to struggle with modest efficacy and significant off-target toxicity. Concurrent with the struggles of the ADC field, a new generation of immune-activating therapeutics has arisen, most clearly exemplified by the PD-1/PD-L1 inhibitors that are now part of standard-of-care treatment regimens for a variety of cancers. The success of these immuno-oncology therapeutic agents has prompted the investigation of a variety of new immuno-stimulant approaches, including toll-like receptor (TLR) activators. Herein, we describe the optimization of ADC technology for the selective delivery of a potent series of TLR7 agonists. A series of imidazole[4,5-c]quinoline agonists (as exemplified by compound 1) were shown to selectively agonize the human and mouse TLR7 receptor at low nanomolar concentrations, resulting in the release of IFNα from human peripheral blood mononuclear cells (hPBMCs) and the upregulation of CD86 on antigen-presenting cells. Compound 1 was attached to a deglycosylated (Fc-γ null) HER2-targeting antibody via a cleavable linker, resulting in an ADC (anti-HER2_vc-1) that potently and selectively activated the TLR7 pathway in tumor-associated macrophages via a "bystander" mechanism. We demonstrated that this ADC rapidly released the TLR7 agonist into the media when incubated with HER2+ cells. This release was not observed upon incubation with an isotype control ADC and furthermore was suppressed by co-administration of the naked antibody. In co-culture experiments with HER2+ HCC1954 cells, this ADC induced the activation of the NFκB pathway in mouse macrophages and the release of IFNα from hPBMCs, while a corresponding isotype control ADC did not. Finally, we demonstrated that IP administration of anti-HER2_vc-1 induced complete tumor regression in an HCC1954 xenograft study in SCID beige mice. Unlike related ADC technology that has been reported recently, our technology relies on the passive diffusion of the TLR7 agonist into tumor-associated macrophages rather than Fc-γ-mediated uptake. Based on these observations, we believe that this ADC technology holds significant potential for both oncology and infectious disease applications.
Collapse
Affiliation(s)
- Siteng Fang
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University, P.O. Box 6000, Binghamton, New York 13902, United States
| | - Brittany M Brems
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University, P.O. Box 6000, Binghamton, New York 13902, United States
| | - Emmanuel O Olawode
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University, P.O. Box 6000, Binghamton, New York 13902, United States
| | - Jared T Miller
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University, P.O. Box 6000, Binghamton, New York 13902, United States
| | - Tracy A Brooks
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University, P.O. Box 6000, Binghamton, New York 13902, United States
| | - L Nathan Tumey
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University, P.O. Box 6000, Binghamton, New York 13902, United States
| |
Collapse
|
7
|
Psaras AM, Miller J, Tumey LN, Brooks TA. Abstract 1246: Anticancer activitiy of indolo[2,3-c]quinoline stabilization of the KRAS promoter G4mid structure. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-1246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
KRAS is a well validated anti-cancer therapeutic target; many active drug discovery programs are ongoing with foci on individual mutant isoforms, necessitating a wide array of drugs to be developed and missing cancers with dysregulation of non-mutant KRAS. Transcriptional down-regulation has been demonstrated to be lethal to tumor cells with aberrant KRAS signaling, irrespective of mutational status, and to potentially have a wide therapeutic window. G-quadruplex (G4) formation within KRAS's core promoter offers a molecular target to decrease the gene expression. Targeted G4-stabilization within the KRAS promoter targets cancer cells' acquired addiction to the transforming event of aberrant KRAS signaling through an activating mutation or protein overexpression, and thus is applicable to both of these deviant states. Small molecules that specifically inhibit transcriptional expression of KRAS genes have great potential for patients whose tumors have disregulated KRAS function. In the current works, compounds clarify the physiologically relevant G4 within the KRAS promoter (G4mid) through a combination of ex vivo screening, luciferase, cytotoxicity, and transcriptional regulation assays. A small set of novel indolo[2,3-c]quinoline compounds were synthesized and a newly optimized FRET Melt2 assay with a Z' score of >0.5 was used to determine KRAS G4mid stabilization efficacy and selectivity. Compounds were then examined for KRAS promoter stabilization using a luciferase assay, pancreatic and ovarian cancer cytotoxicity by an MTS assay, and correlative changes in KRAS transcription as measured by multiplexed qPCR. JM-222 is the lead indolo[2,3-c]quinoline compound that demonstrates KRAS G4mid selective stabilization and promoter regulation, cancer cell cytotoxicity and altered KRAS transcription. These works highlight the function of G4mid in regulating KRAS transcription, novel synthetic methods for indolo[2,3-c]quinoline synthesis, the improved utility of the FRET Melt2 assay, and the overall potential for small compound-mediated KRAS promoter G4 stabilization for patients harboring tumors with aberrant KRAS signaling.
Citation Format: Alexandra Maria Psaras, Jared Miller, L. Nathan Tumey, Tracy A. Brooks. Anticancer activitiy of indolo[2,3-c]quinoline stabilization of the KRAS promoter G4mid structure [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1246.
Collapse
|
8
|
Miller JT, Vitro CN, Fang S, Benjamin SR, Tumey LN. Enzyme-Agnostic Lysosomal Screen Identifies New Legumain-Cleavable ADC Linkers. Bioconjug Chem 2021; 32:842-858. [PMID: 33788548 DOI: 10.1021/acs.bioconjchem.1c00124] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Over the past two decades, antibody drug conjugates (ADCs) and small molecule drug conjugates (SMDCs) have widely employed valine-citruline and related cathepsin-cleavable linkers due to their stability in plasma and their rapid cleavage by lysosomal cathepsins. However, a number of recent studies have illustrated that these linkers are subject to cleavage by exogenous enzymes such as Ces1C and neutrophil elastase, thus resulting in off-target release of drug. As such, there is a need to diversify the portfolio of ADC linkers in order to overcome nonspecific drug release. Rather than targeting cathepsins, we began with an "enzyme agnostic" screen in which a panel of 75 peptide FRET pairs were screened for cleavage in lysosomal extracts and in plasma. Unexpectedly, a series of Asn-containing peptides emerged from this screen as being cleaved far more quickly than traditional ValCit-type linkers while retaining excellent stability in plasma. Catabolism studies demonstrated that these linkers were cleaved by legumain, an asparaginyl endopeptidase that is overexpressed in a variety of cancers and is known to be present in the lysosome. MMAE-containing ADCs that incorporated these new linkers were shown to exhibit highly potent and selective cytotoxicity, comparable to analogous ValCit ADCs. Importantly, the Asn-containing linkers were shown to be completely stable to human neutrophil elastase, an enzyme thought to be responsible for the neutropenia and thrombocytopenia associated with ValCitPABC-MMAE ADCs. The legumain-cleavable ADCs were shown to have excellent stability in both mouse and human serum, retaining >85% of the drug after 1 week of incubation. Moreover, the corresponding small molecule FRET pairs exhibited <10% cleavage after 18 h in mouse and human serum. On the basis of these results, we believe that these new linkers (AsnAsn in particular) have significant potential in both ADC and SMDC drug delivery applications.
Collapse
Affiliation(s)
- Jared T Miller
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University, P.O. Box 6000, Binghamton, New York 13902, United States
| | - Caitlin N Vitro
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University, P.O. Box 6000, Binghamton, New York 13902, United States
| | - Siteng Fang
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University, P.O. Box 6000, Binghamton, New York 13902, United States
| | - Samantha R Benjamin
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University, P.O. Box 6000, Binghamton, New York 13902, United States
| | - L Nathan Tumey
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University, P.O. Box 6000, Binghamton, New York 13902, United States
| |
Collapse
|
9
|
Han YC, Kahler J, Piché-Nicholas N, Hu W, Thibault S, Jiang F, Leal M, Katragadda M, Maderna A, Dushin R, Prashad N, Charati MB, Clark T, Tumey LN, Tan X, Giannakou A, Rosfjord E, Gerber HP, Tchistiakova L, Loganzo F, O'Donnell CJ, Sapra P. Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia. Clin Cancer Res 2021; 27:622-631. [PMID: 33148666 DOI: 10.1158/1078-0432.ccr-20-2149] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2020] [Revised: 08/15/2020] [Accepted: 10/29/2020] [Indexed: 11/16/2022]
Abstract
PURPOSE Mortality due to acute myeloid leukemia (AML) remains high, and the management of relapsed or refractory AML continues to be therapeutically challenging. The reapproval of Mylotarg, an anti-CD33-calicheamicin antibody-drug conjugate (ADC), has provided a proof of concept for an ADC-based therapeutic for AML. Several other ADCs have since entered clinical development of AML, but have met with limited success. We sought to develop a next-generation ADC for AML with a wide therapeutic index (TI) that overcomes the shortcomings of previous generations of ADCs. EXPERIMENTAL DESIGN We compared the TI of our novel CD33-targeted ADC platform with other currently available CD33-targeted ADCs in preclinical models of AML. Next, using this next-generation ADC platform, we performed a head-to-head comparison of two attractive AML antigens, CD33 and CD123. RESULTS Our novel ADC platform offered improved safety and TI when compared with certain currently available ADC platforms in preclinical models of AML. Differentiation between the CD33- and CD123-targeted ADCs was observed in safety studies conducted in cynomolgus monkeys. The CD33-targeted ADC produced severe hematologic toxicity, whereas minimal hematologic toxicity was observed with the CD123-targeted ADC at the same doses and exposures. The improved toxicity profile of an ADC targeting CD123 over CD33 was consistent with the more restricted expression of CD123 in normal tissues. CONCLUSIONS We optimized all components of ADC design (i.e., leukemia antigen, antibody, and linker-payload) to develop an ADC that has the potential to translate into an effective new therapy against AML.
Collapse
Affiliation(s)
- Yoon-Chi Han
- Pfizer Inc., Oncology Research & Development, Pearl River, New York.
| | - Jennifer Kahler
- Pfizer Inc., Oncology Research & Development, Pearl River, New York
| | | | - Wenyue Hu
- Pfizer Inc., Drug Safety Research & Development, La Jolla, California
| | - Stephane Thibault
- Pfizer Inc., Drug Safety Research & Development, La Jolla, California
| | - Fan Jiang
- Pfizer Inc., Oncology Research & Development, Pearl River, New York
| | - Mauricio Leal
- Pfizer Inc., BioMedicine Design, Cambridge, Massachusetts and Pearl River, New York
| | - Madan Katragadda
- Pfizer Inc., BioMedicine Design, Cambridge, Massachusetts and Pearl River, New York
| | - Andreas Maderna
- Pfizer Inc., Worldwide Medicinal Chemistry, Groton, Connecticut
| | - Russell Dushin
- Pfizer Inc., Worldwide Medicinal Chemistry, Groton, Connecticut
| | - Nadira Prashad
- Pfizer Inc., Oncology Research & Development, Pearl River, New York
| | - Manoj B Charati
- Pfizer Inc., Oncology Research & Development, Pearl River, New York
| | | | - L Nathan Tumey
- Pfizer Inc., Worldwide Medicinal Chemistry, Groton, Connecticut
| | - Xingzhi Tan
- Pfizer Inc., Oncology Research & Development, Pearl River, New York
| | | | - Edward Rosfjord
- Pfizer Inc., Oncology Research & Development, Pearl River, New York
| | | | | | - Frank Loganzo
- Pfizer Inc., Oncology Research & Development, Pearl River, New York
| | | | - Puja Sapra
- Pfizer Inc., Oncology Research & Development, Pearl River, New York.
| |
Collapse
|
10
|
Chio TI, Demestichas BR, Brems BM, Bane SL, Tumey LN. Expanding the Versatility of Microbial Transglutaminase Using α‐Effect Nucleophiles as Noncanonical Substrates. Angew Chem Int Ed Engl 2020. [DOI: 10.1002/ange.202001830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Tak Ian Chio
- Department of Chemistry Binghamton University State University of New York 25 Murray Hill Rd Vestal NY 13850 USA
| | - Breanna R. Demestichas
- Department of Chemistry Binghamton University State University of New York 25 Murray Hill Rd Vestal NY 13850 USA
| | - Brittany M. Brems
- Department of Pharmaceutical Sciences Binghamton University State University of New York 96 Corliss Ave Johnson City NY 13790 USA
| | - Susan L. Bane
- Department of Chemistry Binghamton University State University of New York 25 Murray Hill Rd Vestal NY 13850 USA
| | - L. Nathan Tumey
- Department of Pharmaceutical Sciences Binghamton University State University of New York 96 Corliss Ave Johnson City NY 13790 USA
| |
Collapse
|
11
|
Graziani EI, Sung M, Ma D, Narayanan B, Marquette K, Puthenveetil S, Tumey LN, Bikker J, Casavant J, Bennett EM, Charati MB, Golas J, Hosselet C, Rohde CM, Hu G, Guffroy M, Falahatpisheh H, Finkelstein M, Clark T, Barletta F, Tchistiakova L, Lucas J, Rosfjord E, Loganzo F, O'Donnell CJ, Gerber HP, Sapra P. PF-06804103, A Site-specific Anti-HER2 Antibody-Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers. Mol Cancer Ther 2020; 19:2068-2078. [PMID: 32747418 DOI: 10.1158/1535-7163.mct-20-0237] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2020] [Revised: 06/04/2020] [Accepted: 07/14/2020] [Indexed: 11/16/2022]
Abstract
The approval of ado-trastuzumab emtansine (T-DM1) in HER2+ metastatic breast cancer validated HER2 as a target for HER2-specific antibody-drug conjugates (ADC). Despite its demonstrated clinical efficacy, certain inherent properties within T-DM1 hamper this compound from achieving the full potential of targeting HER2-expressing solid tumors with ADCs. Here, we detail the discovery of PF-06804103, an anti-HER2 ADC designed to have a widened therapeutic window compared with T-DM1. We utilized an empirical conjugation site screening campaign to identify the engineered ĸkK183C and K290C residues as those that maximized in vivo ADC stability, efficacy, and safety for a four drug-antibody ratio (DAR) ADC with this linker-payload combination. PF-06804103 incorporates the following novel design elements: (i) a new auristatin payload with optimized pharmacodynamic properties, (ii) a cleavable linker for optimized payload release and enhanced antitumor efficacy, and (iii) an engineered cysteine site-specific conjugation approach that overcomes the traditional safety liabilities of conventional conjugates and generates a homogenous drug product with a DAR of 4. PF-06804103 shows (i) an enhanced efficacy against low HER2-expressing breast, gastric, and lung tumor models, (ii) overcomes in vitro- and in vivo-acquired T-DM1 resistance, and (iii) an improved safety profile by enhancing ADC stability, pharmacokinetic parameters, and reducing off-target toxicities. Herein, we showcase our platform approach in optimizing ADC design, resulting in the generation of the anti-HER2 ADC, PF-06804103. The design elements of identifying novel sites of conjugation employed in this study serve as a platform for developing optimized ADCs against other tumor-specific targets.
Collapse
Affiliation(s)
| | - Matthew Sung
- Pfizer Inc., Oncology Research & Development, Pearl River, New York.
| | - Dangshe Ma
- Pfizer Inc., Oncology Research & Development, Pearl River, New York
| | - Bitha Narayanan
- Pfizer Inc., Oncology Research & Development, Pearl River, New York
| | | | | | - L Nathan Tumey
- Pfizer Inc., World Wide Medicinal Chemistry, Groton, Connecticut
| | - Jack Bikker
- Pfizer Inc., World Wide Medicinal Chemistry, Groton, Connecticut
| | - Jeffrey Casavant
- Pfizer Inc., World Wide Medicinal Chemistry, Groton, Connecticut
| | - Eric M Bennett
- Pfizer Inc., BioMedicine Design, Cambridge, Massachusetts
| | - Manoj B Charati
- Pfizer Inc., Oncology Research & Development, Pearl River, New York
| | - Jonathon Golas
- Pfizer Inc., Oncology Research & Development, Pearl River, New York
| | | | - Cynthia M Rohde
- Pfizer Inc., Drug Safety Research & Development, Pearl River, New York
| | - George Hu
- Pfizer Inc., Drug Safety Research & Development, Pearl River, New York
| | - Magali Guffroy
- Pfizer Inc., Drug Safety Research & Development, Pearl River, New York
| | | | | | - Tracey Clark
- Pfizer Inc., BioMedicine Design, Groton, Connecticut
| | | | | | - Judy Lucas
- Pfizer Inc., Oncology Research & Development, Pearl River, New York
| | - Edward Rosfjord
- Pfizer Inc., Oncology Research & Development, Pearl River, New York
| | - Frank Loganzo
- Pfizer Inc., Oncology Research & Development, Pearl River, New York
| | | | | | - Puja Sapra
- Pfizer Inc., Oncology Research & Development, Pearl River, New York.
| |
Collapse
|
12
|
Chio TI, Demestichas BR, Brems BM, Bane SL, Tumey LN. Expanding the Versatility of Microbial Transglutaminase Using α-Effect Nucleophiles as Noncanonical Substrates. Angew Chem Int Ed Engl 2020; 59:13814-13820. [PMID: 32268004 DOI: 10.1002/anie.202001830] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2020] [Revised: 04/03/2020] [Indexed: 12/12/2022]
Abstract
The substrate promiscuity of microbial transglutaminase (mTG) has been exploited in various applications in biotechnology, in particular for the attachment of alkyl amines to glutamine-containing peptides and proteins. Here, we expand the substrate repertoire to include hydrazines, hydrazides, and alkoxyamines, resulting in the formation of isopeptide bonds with varied susceptibilities to hydrolysis or exchange by mTG. Furthermore, we demonstrate that simple unsubstituted hydrazine and dihydrazides can be used to install reactive hydrazide handles onto the side chain of internal glutamine residues. The distinct hydrazide handles can be further coupled with carbonyls, including ortho-carbonylphenylboronic acids, to form site-specific and functional bioconjugates with tunable hydrolytic stability. The extension of the substrate scope of mTG beyond canonical amines thus substantially broadens the versatility of the enzyme, providing a new approach to facilitate novel applications.
Collapse
Affiliation(s)
- Tak Ian Chio
- Department of Chemistry, Binghamton University, State University of New York, 25 Murray Hill Rd, Vestal, NY, 13850, USA
| | - Breanna R Demestichas
- Department of Chemistry, Binghamton University, State University of New York, 25 Murray Hill Rd, Vestal, NY, 13850, USA
| | - Brittany M Brems
- Department of Pharmaceutical Sciences, Binghamton University, State University of New York, 96 Corliss Ave, Johnson City, NY, 13790, USA
| | - Susan L Bane
- Department of Chemistry, Binghamton University, State University of New York, 25 Murray Hill Rd, Vestal, NY, 13850, USA
| | - L Nathan Tumey
- Department of Pharmaceutical Sciences, Binghamton University, State University of New York, 96 Corliss Ave, Johnson City, NY, 13790, USA
| |
Collapse
|
13
|
Shakeraneh P, Robinson R, Kufel WD, Tumey LN, Benjamin SR, Miller CD, Darko W, Probst LA, Seabury RW. Chemical and Physical Stability of an Admixture Containing Cefepime and Vancomycin in Lactated Ringer Solution. Hosp Pharm 2020; 56:338-342. [PMID: 34381271 DOI: 10.1177/0018578719901278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Purpose: To evaluate the chemical and physical stability of an admixture containing cefepime and vancomycin in a single volume of lactated Ringer solution at refrigerated temperatures. Methods: Cefepime 2000 mg and vancomycin 1000 mg were, respectively, reconstituted with 10 and 20 mL of sterile water for injection (SWFI) per manufacturer instructions. This resulted in cefepime and vancomycin concentrations of 200 and 50 mg/mL, respectively. The resulting cefepime and vancomycin solutions at 10 and 20 mL, respectively, were drawn up and injected into 1000 mL lactated Ringer solution. Aliquot samples were obtained on days 0 to 9, visually inspected for gross incompatibility, and then stored at -80°C. Samples were thawed on the day of the analysis and run through ultraperformance liquid chromatography. Area under the concentration-time curve (AUC) on each day was compared with baseline AUC values. Chemical stability was defined as an AUC more than 93% of the baseline value. Results: No evidence of gross physical incompatibility was observed by visual inspection. Cefepime and vancomycin replicants were more than 94.5% and 98% of baseline AUC values. Therefore, all sample replicants were found to be more than 93% of their baseline AUC value. Conclusion: An admixture containing cefepime 2000 mg and vancomycin 1000 mg in 1000 mL lactated Ringer solution appears to be chemically and physically stable at refrigerated temperatures for up to 9 days.
Collapse
Affiliation(s)
- Pegah Shakeraneh
- State University of New York Upstate University Hospital, Syracuse, NY, USA
| | - Risako Robinson
- State University of New York Upstate University Hospital, Syracuse, NY, USA
| | - Wesley D Kufel
- State University of New York Upstate University Hospital, Syracuse, NY, USA.,Binghamton University School of Pharmacy and Pharmaceutical Sciences, Binghamton, NY, USA.,State University of New York Upstate Medical University, Syracuse, NY, USA
| | - L Nathan Tumey
- Binghamton University School of Pharmacy and Pharmaceutical Sciences, Binghamton, NY, USA
| | - Samantha R Benjamin
- Binghamton University School of Pharmacy and Pharmaceutical Sciences, Binghamton, NY, USA
| | - Christopher D Miller
- State University of New York Upstate University Hospital, Syracuse, NY, USA.,State University of New York Upstate Medical University, Syracuse, NY, USA
| | - William Darko
- State University of New York Upstate University Hospital, Syracuse, NY, USA
| | - Luke A Probst
- State University of New York Upstate University Hospital, Syracuse, NY, USA.,State University of New York Upstate Medical University, Syracuse, NY, USA
| | - Robert W Seabury
- State University of New York Upstate University Hospital, Syracuse, NY, USA.,State University of New York Upstate Medical University, Syracuse, NY, USA
| |
Collapse
|
14
|
Abstract
The prototypical ADC mechanism involving antigen-mediated uptake and lysosomal release is both elegantly simple and scientifically compelling. However, recent clinical-stage failures have prompted a reevaluation of this delivery paradigm and have resulted in an array of new technologies that have the potential to improve the safety and efficacy of up and coming programs. These innovations can generally be categorized into seven areas that will be elaborated on in this chapter: (1) Exploiting new payload mechanisms; (2) Increasing the drug-antibody ratio (DAR); (3) Increasing the antibody penetration; (4) Overcoming ADC resistance mechanisms; (5) Increasing the efficiency of ADC uptake and processing; (6) Mitigating off-target payload exposure; and (7) Employment of noncytotoxic payloads. It is our belief that these seven areas capture the current "landscape" of innovations that are taking place in the design of next-generation ADCs. Together, these advancements are reshaping the ADC field and providing a path forward in the face of the recent clinical setbacks.
Collapse
Affiliation(s)
- L Nathan Tumey
- Department of Pharmacy and Pharmaceutical Sciences, Binghamton University, Binghamton, NY, USA.
- Pfizer Inc., Groton, CT, USA.
| |
Collapse
|
15
|
Abstract
Incomplete removal of free (unconjugated) drug or drug-linker species used to prepare ADCs results in contaminated ADC samples which may pose a risk for toxicity. Due to the extreme potency of typical small molecule toxins employed in ADCs, even relatively low levels of free drug contaminants in ADC samples have been hypothesized to result in nonspecific (i.e., off-target) activity in biological systems. It is possible for trace levels of certain free drug species to persist in final ADC samples despite the inclusion of common purification steps during the preparation processes. Therefore, methods for the detection, quantification, and removal of residual free drug present in ADC samples are ultimately required for the preparation of safe and efficacious final ADC drug products. Herein we report general methods for the detection and removal of such contaminants.
Collapse
Affiliation(s)
| | | | - Sujiet Puthenveetil
- AbbVie Bioresearch Center, R&D, Worchester, MA, USA
- Pfizer, Inc., Groton, CT, USA
| | - L Nathan Tumey
- Department of Pharmacy and Pharmaceutical Sciences, Binghamton University, Binghamton, NY, USA
- Pfizer, Inc., Groton, CT, USA
| |
Collapse
|
16
|
Doughty B, Tumey LN, Williams K. Case report: Albendazole associated psychosis. Ment Health Clin 2019; 9:397-400. [PMID: 31857936 PMCID: PMC6881107 DOI: 10.9740/mhc.2019.11.397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Introduction The association of psychosis with albendazole monotherapy has not been established in current literature. Case Report We present the first reported case of acute psychosis associated with albendazole. Upon cessation of the agent and the introduction of aripiprazole, the patient's psychosis remitted, and the patient did not present for acute treatment in the months to follow. Discussion/Conclusion The temporal relationship and laboratory data support albendazole's role in leading to the aforementioned toxicity. Such reactions, although rare, can drastically impact patient care and may warrant increased provider consideration when choosing to prescribe albendazole.
Collapse
|
17
|
Benjamin SR, Jackson CP, Fang S, Carlson DP, Guo Z, Tumey LN. Thiolation of Q295: Site-Specific Conjugation of Hydrophobic Payloads without the Need for Genetic Engineering. Mol Pharm 2019; 16:2795-2807. [PMID: 31067063 DOI: 10.1021/acs.molpharmaceut.9b00323] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Site-specific conjugation technology frequently relies on antibody engineering to incorporate rare or non-natural amino acids into the primary sequence of the protein. However, when the primary sequence is unknown or when antibody engineering is not feasible, there are very limited options for site-specific protein modification. We have developed a transglutaminase-mediated conjugation that incorporates a thiol at a "privileged" location on deglycosylated antibodies (Q295). Perhaps surprisingly, this conjugation employs a reported transglutaminase inhibitor, cystamine, as the key enzyme substrate. The chemical incorporation of a thiol at the Q295 site allows for the site-specific attachment of a plethora of commonly used and commercially available payloads via maleimide chemistry. Herein, we demonstrate the utility of this method by comparing the conjugatability, plasma stability, and in vitro potency of these site-specific antibody-drug conjugates (ADCs) with analogous endogenous cysteine conjugates. Cytotoxic ADCs prepared using this methodology are shown to exhibit comparable in vitro efficacy to stochastic cysteine conjugates while displaying dramatically improved plasma stability and conjugatability. In particular, we note that this technique appears to be useful for the incorporation of highly hydrophobic linker payloads without the addition of PEG modifiers. We postulate a possible mechanism for this feature by probing the local environment of the Q295 site with two fluorescent probes that are known to be sensitive to the local hydrophobic environment. In summary, we describe a highly practical method for the site-specific conjugation of genetically nonengineered antibodies, which results in plasma-stable ADCs with low intrinsic hydrophobicity. We believe that this technology will find broad utility in the ADC community.
Collapse
Affiliation(s)
- Samantha R Benjamin
- School of Pharmacy and Pharmaceutical Sciences , Binghamton University , P.O. Box 6000, Binghamton , New York 13902 , United States
| | - Courtney P Jackson
- School of Pharmacy and Pharmaceutical Sciences , Binghamton University , P.O. Box 6000, Binghamton , New York 13902 , United States
| | - Siteng Fang
- School of Pharmacy and Pharmaceutical Sciences , Binghamton University , P.O. Box 6000, Binghamton , New York 13902 , United States
| | - Dane P Carlson
- School of Pharmacy and Pharmaceutical Sciences , Binghamton University , P.O. Box 6000, Binghamton , New York 13902 , United States
| | - Zhongyuan Guo
- School of Pharmacy and Pharmaceutical Sciences , Binghamton University , P.O. Box 6000, Binghamton , New York 13902 , United States
| | - L Nathan Tumey
- School of Pharmacy and Pharmaceutical Sciences , Binghamton University , P.O. Box 6000, Binghamton , New York 13902 , United States
| |
Collapse
|
18
|
Chio TI, Gu H, Mukherjee K, Tumey LN, Bane SL. Site-Specific Bioconjugation and Multi-Bioorthogonal Labeling via Rapid Formation of a Boron-Nitrogen Heterocycle. Bioconjug Chem 2019; 30:1554-1564. [PMID: 31026151 PMCID: PMC6585445 DOI: 10.1021/acs.bioconjchem.9b00246] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Precise control of covalent bond formation in the presence of multiple functional groups is pertinent in the development of many next-generation bioconjugates and materials. Strategies derived from bioorthogonal chemistries are contributing greatly in that regard; however, the gain of chemoselectivity is often compromised by the slow rates of many of these existing chemistries. Recent work on a variation of the classical aldehyde/ketone condensation based on ortho-carbonylphenylboronic acids has uncovered markedly accelerated rates compared to those of the simple carbonyl counterparts. The products of these reactions are distinct, often in the form of boron-nitrogen heterocycles. In particular, we have shown that 2-formylphenylboronic acid (2fPBA), when coupled with an α-amino-hydrazide, produces a unique zwitterionic and stable 2,3,1-benzodiazaborine derivative. In this work, we apply this chemistry to generate chemically defined and functional bioconjugates, herein illustrated with immunoconjugates. We show that an antibody and a fluorophore (as payload) equipped with the relevant reactive handles undergo rapid conjugation at near-stoichiometric ratios, displaying a reaction half-life of only ∼5 min with 2 equiv of the linker payload. Importantly, the reaction can be extended to multicomponent labeling by partnering with the popular strain-promoted azide-alkyne cycloaddition and tetrazine- trans-cyclooctene (Tz-TCO) ligation. The mutual orthogonality to both of these chemistries allows simultaneous triple bioorthogonal conjugations, a rare feat thus far that will widen the scope of various multilabeling applications. Further collaboration with the Tz-TCO reaction enables rapid one-pot synthesis of a site-specific dual-payload antibody conjugate. Altogether, we envision that the 2fPBA-α-amino-hydrazide ligation will facilitate efficient assembly of diverse bioconjugates and materials, enabling access to more complex modalities via partnership with other orthogonal chemistries.
Collapse
Affiliation(s)
- Tak Ian Chio
- Department of Chemistry, Binghamton University, State University of New York, Binghamton, New York 13902, United States
| | - Han Gu
- Department of Chemistry, Binghamton University, State University of New York, Binghamton, New York 13902, United States
| | - Kamalika Mukherjee
- Department of Chemistry, Binghamton University, State University of New York, Binghamton, New York 13902, United States
| | - L. Nathan Tumey
- Department of Pharmaceutical Sciences, Binghamton University, State University of New York, Binghamton, New York 13902, United States
| | - Susan L. Bane
- Department of Chemistry, Binghamton University, State University of New York, Binghamton, New York 13902, United States
| |
Collapse
|
19
|
Ratnayake AS, Chang LP, Tumey LN, Loganzo F, Chemler JA, Wagenaar M, Musto S, Li F, Janso JE, Ballard TE, Rago B, Steele GL, Ding W, Feng X, Hosselet C, Buklan V, Lucas J, Koehn FE, O'Donnell CJ, Graziani EI. Natural Product Bis-Intercalator Depsipeptides as a New Class of Payloads for Antibody-Drug Conjugates. Bioconjug Chem 2018; 30:200-209. [PMID: 30543418 DOI: 10.1021/acs.bioconjchem.8b00843] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
A potent class of DNA-damaging agents, natural product bis-intercalator depsipeptides (NPBIDs), was evaluated as ultrapotent payloads for use in antibody-drug conjugates (ADCs). Detailed investigation of potency (both in cells and via biophysical characterization of DNA binding), chemical tractability, and in vitro and in vivo stability of the compounds in this class eliminated a number of potential candidates, greatly reducing the complexity and resources required for conjugate preparation and evaluation. This effort yielded a potent, stable, and efficacious ADC, PF-06888667, consisting of the bis-intercalator, SW-163D, conjugated via an N-acetyl-lysine-valine-citrulline- p-aminobenzyl alcohol- N, N-dimethylethylenediamine (AcLysValCit-PABC-DMAE) linker to an engineered variant of the anti-Her2 mAb, trastuzumab, catalyzed by transglutaminase.
Collapse
Affiliation(s)
- Anokha S Ratnayake
- Medicine Design , Pfizer Worldwide Research and Development , 445 Eastern Point Road , Groton , Connecticut 06340 , United States
| | - Li-Ping Chang
- Medicine Design , Pfizer Worldwide Research and Development , 445 Eastern Point Road , Groton , Connecticut 06340 , United States
| | - L Nathan Tumey
- Medicine Design , Pfizer Worldwide Research and Development , 445 Eastern Point Road , Groton , Connecticut 06340 , United States
| | - Frank Loganzo
- Oncology Research , Pfizer Worldwide Research and Development , 401 North Middletown Road , Pearl River , New York 10965 , United States
| | - Joseph A Chemler
- Medicine Design , Pfizer Worldwide Research and Development , 445 Eastern Point Road , Groton , Connecticut 06340 , United States
| | - Melissa Wagenaar
- Medicine Design , Pfizer Worldwide Research and Development , 445 Eastern Point Road , Groton , Connecticut 06340 , United States
| | - Sylvia Musto
- Oncology Research , Pfizer Worldwide Research and Development , 401 North Middletown Road , Pearl River , New York 10965 , United States
| | - Fengping Li
- Medicine Design , Pfizer Worldwide Research and Development , 445 Eastern Point Road , Groton , Connecticut 06340 , United States
| | - Jeffrey E Janso
- Medicine Design , Pfizer Worldwide Research and Development , 445 Eastern Point Road , Groton , Connecticut 06340 , United States
| | - T Eric Ballard
- Medicine Design , Pfizer Worldwide Research and Development , 445 Eastern Point Road , Groton , Connecticut 06340 , United States
| | - Brian Rago
- Medicine Design , Pfizer Worldwide Research and Development , 445 Eastern Point Road , Groton , Connecticut 06340 , United States
| | - Greg L Steele
- Medicine Design , Pfizer Worldwide Research and Development , 445 Eastern Point Road , Groton , Connecticut 06340 , United States
| | - WeiDong Ding
- Medicine Design , Pfizer Worldwide Research and Development , 445 Eastern Point Road , Groton , Connecticut 06340 , United States
| | - Xidong Feng
- Medicine Design , Pfizer Worldwide Research and Development , 445 Eastern Point Road , Groton , Connecticut 06340 , United States
| | - Christine Hosselet
- Oncology Research , Pfizer Worldwide Research and Development , 401 North Middletown Road , Pearl River , New York 10965 , United States
| | - Vlad Buklan
- Oncology Research , Pfizer Worldwide Research and Development , 401 North Middletown Road , Pearl River , New York 10965 , United States
| | - Judy Lucas
- Oncology Research , Pfizer Worldwide Research and Development , 401 North Middletown Road , Pearl River , New York 10965 , United States
| | - Frank E Koehn
- Medicine Design , Pfizer Worldwide Research and Development , 445 Eastern Point Road , Groton , Connecticut 06340 , United States
| | - Christopher J O'Donnell
- Medicine Design , Pfizer Worldwide Research and Development , 445 Eastern Point Road , Groton , Connecticut 06340 , United States
| | - Edmund I Graziani
- Medicine Design , Pfizer Worldwide Research and Development , 445 Eastern Point Road , Groton , Connecticut 06340 , United States
| |
Collapse
|
20
|
Tumey LN, Han S. ADME Considerations for the Development of Biopharmaceutical Conjugates Using Cleavable Linkers. Curr Top Med Chem 2018; 17:3444-3462. [DOI: 10.2174/1568026618666180118154017] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2017] [Revised: 12/29/2017] [Accepted: 01/11/2018] [Indexed: 11/22/2022]
Affiliation(s)
- L. Nathan Tumey
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University, PO Box 6000, Binghamton, NY 13902- 6000, United States
| | - Sean Han
- PKDM, AMGEN Inc., 360 Binney St., Cambridge MA 02142, United States
| |
Collapse
|
21
|
Tumey LN, Li F, Rago B, Han X, Loganzo F, Musto S, Graziani EI, Puthenveetil S, Casavant J, Marquette K, Clark T, Bikker J, Bennett EM, Barletta F, Piche-Nicholas N, Tam A, O'Donnell CJ, Gerber HP, Tchistiakova L. Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates. AAPS J 2017; 19:1123-1135. [PMID: 28439809 DOI: 10.1208/s12248-017-0083-7] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/09/2017] [Accepted: 04/03/2017] [Indexed: 11/30/2022]
Abstract
As the antibody drug conjugate (ADC) community continues to shift towards site-specific conjugation technology, there is a growing need to understand how the site of conjugation impacts the biophysical and biological properties of an ADC. In order to address this need, we prepared a carefully selected series of engineered cysteine ADCs and proceeded to systematically evaluate their potency, stability, and PK exposure. The site of conjugation did not have a significant influence on the thermal stability and in vitro cytotoxicity of the ADCs. However, we demonstrate that the rate of cathepsin-mediated linker cleavage is heavily dependent upon site and is closely correlated with ADC hydrophobicity, thus confirming other recent reports of this phenomenon. Interestingly, conjugates with high rates of cathepsin-mediated linker cleavage did not exhibit decreased plasma stability. In fact, the major source of plasma instability was shown to be retro-Michael mediated deconjugation. This process is known to be impeded by succinimide hydrolysis, and thus, we undertook a series of mutational experiments demonstrating that basic residues located nearby the site of conjugation can be a significant driver of succinimide ring opening. Finally, we show that total antibody PK exposure in rat was loosely correlated with ADC hydrophobicity. It is our hope that these observations will help the ADC community to build "design rules" that will enable more efficient prosecution of next-generation ADC discovery programs.
Collapse
Affiliation(s)
- L Nathan Tumey
- Binghamton University, School of Pharmacy and Pharmaceutical Sciences, P.O. Box 6000, Binghamton, New York, 13902-6000, USA.
| | - Fengping Li
- Biomedicine Design, Pfizer, Inc., Cambridge, Massachusetts, 06379, USA
| | - Brian Rago
- Worldwide Research and Development, Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut, 06379, USA
| | - Xiaogang Han
- PKDM, Amgen, Inc., 360 Binney Street, AMA 1, Cambridge, Massachusetts, 02142, USA
| | - Frank Loganzo
- Oncology Research and Development, Pfizer, Inc., 401 N. Middletown Rd., Pearl River, New York, 10965, USA
| | - Sylvia Musto
- Oncology Research and Development, Pfizer, Inc., 401 N. Middletown Rd., Pearl River, New York, 10965, USA
| | - Edmund I Graziani
- Worldwide Research and Development, Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut, 06379, USA
| | | | - Jeffrey Casavant
- Worldwide Research and Development, Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut, 06379, USA
| | | | - Tracey Clark
- Worldwide Research and Development, Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut, 06379, USA
| | - Jack Bikker
- International Flavors and Fragrances, 521 West 57th Street, New York, New York, 10019, USA
| | - Eric M Bennett
- Biomedicine Design, Pfizer, Inc., Cambridge, Massachusetts, 06379, USA
| | - Frank Barletta
- Worldwide Research and Development, Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut, 06379, USA
| | | | - Amy Tam
- Biomedicine Design, Pfizer, Inc., Cambridge, Massachusetts, 06379, USA
| | - Christopher J O'Donnell
- Worldwide Research and Development, Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut, 06379, USA
| | - Hans Peter Gerber
- Maverick Therapeutics, Inc, 3260 Bayshore Blvd, Brisbane, California, 94005, USA
| | | |
Collapse
|
22
|
Rago B, Tumey LN, Wei C, Barletta F, Clark T, Hansel S, Han X. Quantitative Conjugated Payload Measurement Using Enzymatic Release of Antibody–Drug Conjugate with Cleavable Linker. Bioconjug Chem 2017; 28:620-626. [DOI: 10.1021/acs.bioconjchem.6b00695] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Brian Rago
- Medicine Design, ‡Biomedicine Design, and §Pfizer Essential Health, Pfizer Inc., Eastern
Point Road, Groton, Connecticut 06340, United States
| | - L. Nathan Tumey
- Medicine Design, ‡Biomedicine Design, and §Pfizer Essential Health, Pfizer Inc., Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Cong Wei
- Medicine Design, ‡Biomedicine Design, and §Pfizer Essential Health, Pfizer Inc., Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Frank Barletta
- Medicine Design, ‡Biomedicine Design, and §Pfizer Essential Health, Pfizer Inc., Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Tracey Clark
- Medicine Design, ‡Biomedicine Design, and §Pfizer Essential Health, Pfizer Inc., Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Steven Hansel
- Medicine Design, ‡Biomedicine Design, and §Pfizer Essential Health, Pfizer Inc., Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Xiaogang Han
- Medicine Design, ‡Biomedicine Design, and §Pfizer Essential Health, Pfizer Inc., Eastern
Point Road, Groton, Connecticut 06340, United States
| |
Collapse
|
23
|
Tumey LN, Leverett CA, Vetelino B, Li F, Rago B, Han X, Loganzo F, Musto S, Bai G, Sukuru SCK, Graziani EI, Puthenveetil S, Casavant J, Ratnayake A, Marquette K, Hudson S, Doppalapudi VR, Stock J, Tchistiakova L, Bessire AJ, Clark T, Lucas J, Hosselet C, O’Donnell CJ, Subramanyam C. Optimization of Tubulysin Antibody-Drug Conjugates: A Case Study in Addressing ADC Metabolism. ACS Med Chem Lett 2016; 7:977-982. [PMID: 27882194 PMCID: PMC5108037 DOI: 10.1021/acsmedchemlett.6b00195] [Citation(s) in RCA: 50] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2016] [Accepted: 06/22/2016] [Indexed: 01/19/2023] Open
Abstract
As part of our efforts to develop new classes of tubulin inhibitor payloads for antibody-drug conjugate (ADC) programs, we developed a tubulysin ADC that demonstrated excellent in vitro activity but suffered from rapid metabolism of a critical acetate ester. A two-pronged strategy was employed to address this metabolism. First, the hydrolytically labile ester was replaced by a carbamate functional group resulting in a more stable ADC that retained potency in cellular assays. Second, site-specific conjugation was employed in order to design ADCs with reduced metabolic liabilities. Using the later approach, we were able to identify a conjugate at the 334C position of the heavy chain that resulted in an ADC with considerably reduced metabolism and improved efficacy. The examples discussed herein provide one of the clearest demonstrations to-date that site of conjugation can play a critical role in addressing metabolic and PK liabilities of an ADC. Moreover, a clear correlation was identified between the hydrophobicity of an ADC and its susceptibility to metabolic enzymes. Importantly, this study demonstrates that traditional medicinal chemistry strategies can be effectively applied to ADC programs.
Collapse
Affiliation(s)
- L. Nathan Tumey
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Carolyn A. Leverett
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Beth Vetelino
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Fengping Li
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Brian Rago
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Xiaogang Han
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Frank Loganzo
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Sylvia Musto
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Guoyun Bai
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | | | - Edmund I. Graziani
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Sujiet Puthenveetil
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Jeffrey Casavant
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Anokha Ratnayake
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Kimberly Marquette
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Sarah Hudson
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | | | - Joseph Stock
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | | | - Andrew J. Bessire
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Tracey Clark
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Judy Lucas
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Christine Hosselet
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | | | | |
Collapse
|
24
|
Puthenveetil S, Loganzo F, He H, Dirico K, Green M, Teske J, Musto S, Clark T, Rago B, Koehn F, Veneziale R, Falahaptisheh H, Han X, Barletta F, Lucas J, Subramanyam C, O'Donnell CJ, Tumey LN, Sapra P, Gerber HP, Ma D, Graziani EI. Natural Product Splicing Inhibitors: A New Class of Antibody-Drug Conjugate (ADC) Payloads. Bioconjug Chem 2016; 27:1880-8. [PMID: 27412791 DOI: 10.1021/acs.bioconjchem.6b00291] [Citation(s) in RCA: 42] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
There is a considerable ongoing work to identify new cytotoxic payloads that are appropriate for antibody-based delivery, acting via mechanisms beyond DNA damage and microtubule disruption, highlighting their importance to the field of cancer therapeutics. New modes of action will allow a more diverse set of tumor types to be targeted and will allow for possible mechanisms to evade the drug resistance that will invariably develop to existing payloads. Spliceosome inhibitors are known to be potent antiproliferative agents capable of targeting both actively dividing and quiescent cells. A series of thailanstatin-antibody conjugates were prepared in order to evaluate their potential utility in the treatment of cancer. After exploring a variety of linkers, we found that the most potent antibody-drug conjugates (ADCs) were derived from direct conjugation of the carboxylic acid-containing payload to surface lysines of the antibody (a "linker-less" conjugate). Activity of these lysine conjugates was correlated to drug-loading, a feature not typically observed for other payload classes. The thailanstatin-conjugates were potent in high target expressing cells, including multidrug-resistant lines, and inactive in nontarget expressing cells. Moreover, these ADCs were shown to promote altered splicing products in N87 cells in vitro, consistent with their putative mechanism of action. In addition, the exposure of the ADCs was sufficient to result in excellent potency in a gastric cancer xenograft model at doses as low as 1.5 mg/kg that was superior to the clinically approved ADC T-DM1. The results presented herein therefore open the door to further exploring splicing inhibition as a potential new mode-of-action for novel ADCs.
Collapse
Affiliation(s)
| | - Frank Loganzo
- Oncology-Rinat Research & Development, Pfizer , 401 North Middletown Road, Pearl River, New York 10965, United States
| | | | | | | | | | - Sylvia Musto
- Oncology-Rinat Research & Development, Pfizer , 401 North Middletown Road, Pearl River, New York 10965, United States
| | | | | | | | - Robert Veneziale
- Drug Safety Research and Development, Pfizer , 401 North Middletown Road, Pearl River, New York 10977, United States
| | - Hadi Falahaptisheh
- Drug Safety Research and Development, Pfizer , 401 North Middletown Road, Pearl River, New York 10977, United States
| | | | | | - Judy Lucas
- Oncology-Rinat Research & Development, Pfizer , 401 North Middletown Road, Pearl River, New York 10965, United States
| | | | | | | | - Puja Sapra
- Oncology-Rinat Research & Development, Pfizer , 401 North Middletown Road, Pearl River, New York 10965, United States
| | - Hans Peter Gerber
- Oncology-Rinat Research & Development, Pfizer , 401 North Middletown Road, Pearl River, New York 10965, United States
| | - Dangshe Ma
- Oncology-Rinat Research & Development, Pfizer , 401 North Middletown Road, Pearl River, New York 10965, United States
| | | |
Collapse
|
25
|
Wei C, Zhang G, Clark T, Barletta F, Tumey LN, Rago B, Hansel S, Han X. Where Did the Linker-Payload Go? A Quantitative Investigation on the Destination of the Released Linker-Payload from an Antibody-Drug Conjugate with a Maleimide Linker in Plasma. Anal Chem 2016; 88:4979-86. [PMID: 27075639 DOI: 10.1021/acs.analchem.6b00976] [Citation(s) in RCA: 57] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The reactive thiol of cysteine is often used for coupling maleimide-containing linker-payloads to antibodies resulting in the generation of antibody drug conjugates (ADCs). Currently, a numbers of ADCs in drug development are made by coupling a linker-payload to native or engineered cysteine residues on the antibody. An ADC conjugated via hinge-cysteines to an auristatin payload was used as a model in this study to understand the impact of the maleimide linkers on ADC stability. The payload was conjugated to trastuzumab by a protease-cleavable linker, maleimido-caproyl-valine-citruline-p-amino-benzyloxy carbonyl (mcVC-PABC). In plasma stability assays, when the ADC (Trastuzumab-mcVC-PABC-Auristatin-0101) was incubated with plasma over a 144-h time-course, a discrepancy was observed between the measured released free payload concentration and the measured loss of drug-to-antibody ratio (DAR), as measured by liquid chromatography-mass spectrometry (LC-MS). We found that an enzymatic release of payload from ADC-depleted human plasma at 144 h was able to account for almost 100% of the DAR loss. Intact protein mass analysis showed that at the 144 h time point, the mass of the major protein in ADC-depleted human plasma had an additional 1347 Da over the native albumin extracted from human plasma, exactly matching the mass of the linker-payload. In addition, protein gel electrophoresis showed that there was only one enriched protein in the 144 h ADC-depleted and antipayload immunoprecipitated plasma sample, as compared to the 0 h plasma immunoprecipitated sample, and the mass of this enriched protein was slightly heavier than the mass of serum albumin. Furthermore, the albumin adduct was also identified in 96 h and 168 h postdose in vivo cynomolgus monkey plasma. These results strongly suggest that the majority of the deconjugated mc-VC-PABC-auristatin ultimately is transferred to serum albumin, forming a long-lived albumin-linker-payload adduct. To our knowledge, this is the first report quantitatively characterizing the extent of linker-payload transfer to serum albumin and the first clear example of in vivo formation of an albumin-linker-payload adduct.
Collapse
Affiliation(s)
- Cong Wei
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Eastern Point Road, Groton, Connecticut 06340, United States
| | - Guodong Zhang
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Eastern Point Road, Groton, Connecticut 06340, United States
| | - Tracey Clark
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Eastern Point Road, Groton, Connecticut 06340, United States
| | - Frank Barletta
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Eastern Point Road, Groton, Connecticut 06340, United States
| | - L Nathan Tumey
- Worldwide Medicinal Chemistry, Pfizer Inc. , Eastern Point Road, Groton, Connecticut 06340, United States
| | - Brian Rago
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Eastern Point Road, Groton, Connecticut 06340, United States
| | - Steven Hansel
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Eastern Point Road, Groton, Connecticut 06340, United States
| | - Xiaogang Han
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Eastern Point Road, Groton, Connecticut 06340, United States
| |
Collapse
|
26
|
Puthenveetil S, Musto S, Loganzo F, Tumey LN, O'Donnell CJ, Graziani E. Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates. Bioconjug Chem 2016; 27:1030-9. [PMID: 26942771 DOI: 10.1021/acs.bioconjchem.6b00054] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The focus of the antibody-drug conjugate (ADC) field is shifting toward development of site-specific, next-generation ADCs to address the issue of heterogeneity, metabolic instability, conjugatability, and less than ideal therapeutic index associated with the conventional (heterogeneous) ADCs. It is evident from the recent literature that the site of conjugation, the structure of the linker, and the physicochemical properties of the linker-payload all have a significant impact on the safety and efficacy of the resulting ADCs. Screening multiple linker-payloads on multiple sites of an antibody presents a combinatorial problem that necessitates high-throughput conjugation and purification methodology to identify ADCs with the best combination of site and payload. Toward this end, we developed a protein A/L-based solid-phase, site-specific conjugation and purification method that can be used to generate site-specific ADCs in a 96-well plate format. This solid-phase method has been shown to be versatile because of its compatibility with various conjugation functional handles such as maleimides, haloacetamides, copper free click substrates, and transglutaminase substrates. The application of this methodology was further expanded to generate dual labeled, site-specific antibody and Fab conjugates.
Collapse
Affiliation(s)
- Sujiet Puthenveetil
- Worldwide Medicinal Chemistry, Pfizer Global R&D , Groton, Connecticut 06340, United States
| | - Sylvia Musto
- Pfizer Oncology-Rinat R&D , 401 North Middletown Road, Pearl River, New York 10965, United States
| | - Frank Loganzo
- Pfizer Oncology-Rinat R&D , 401 North Middletown Road, Pearl River, New York 10965, United States
| | - L Nathan Tumey
- Worldwide Medicinal Chemistry, Pfizer Global R&D , Groton, Connecticut 06340, United States
| | | | - Edmund Graziani
- Worldwide Medicinal Chemistry, Pfizer Global R&D , Groton, Connecticut 06340, United States
| |
Collapse
|
27
|
Tumey LN, Charati M, He T, Sousa E, Ma D, Han X, Clark T, Casavant J, Loganzo F, Barletta F, Lucas J, Graziani EI. Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy. Bioconjug Chem 2014; 25:1871-80. [PMID: 25216346 DOI: 10.1021/bc500357n] [Citation(s) in RCA: 137] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
The stability of the connection between the antibody and the toxin can have a profound impact on ADC safety and efficacy. There has been increasing evidence in recent years that maleimide-based ADCs are prone to payload loss via a retro-Michael type reaction. Herein, we report a mild method for the hydrolysis of the succinimide-thioether ring which results in a "ring-opened" linker. ADCs containing this hydrolyzed succinimide linker show equivalent cytotoxicity, improved in vitro stability, improved PK exposure, and improved efficacy as compared to their nonhydrolyzed counterparts. This method offers a simple way to improve the stability, exposure, and efficacy of maleimide-based ADCs.
Collapse
Affiliation(s)
- L Nathan Tumey
- Worldwide Medicinal Chemistry, ‡Global Biological Technologies, §Pharmacokinetics, Metabolism, and Distribution, and ∥Oncology Research Unit, Pfizer Global R&D , Groton, Connecticut 06340, United States
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Tumey LN, Boschelli DH, Bhagirath N, Shim J, Murphy EA, Goodwin D, Bennett EM, Wang M, Lin LL, Press B, Shen M, Frisbie RK, Morgan P, Mohan S, Shin J, Rao VR. Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4. Bioorg Med Chem Lett 2014; 24:2066-72. [PMID: 24726805 DOI: 10.1016/j.bmcl.2014.03.056] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2014] [Revised: 03/17/2014] [Accepted: 03/18/2014] [Indexed: 10/25/2022]
Abstract
IRAK4 is responsible for initiating signaling from Toll-like receptors (TLRs) and members of the IL-1/18 receptor family. Kinase-inactive knock-ins and targeted deletions of IRAK4 in mice cause reductions in TLR induced pro-inflammatory cytokines and these mice are resistant to various models of arthritis. Herein we report the identification and optimization of a series of potent IRAK4 inhibitors. Representative examples from this series showed excellent selectivity over a panel of kinases, including the kinases known to play a role in TLR-mediated signaling. The compounds exhibited low nM potency in LPS- and R848-induced cytokine assays indicating that they are blocking the TLR signaling pathway. A key compound (26) from this series was profiled in more detail and found to have an excellent pharmaceutical profile as measured by predictive assays such as microsomal stability, TPSA, solubility, and clogP. However, this compound was found to afford poor exposure in mouse upon IP or IV administration. We found that removal of the ionizable solubilizing group (32) led to increased exposure, presumably due to increased permeability. Compounds 26 and 32, when dosed to plasma levels corresponding to ex vivo whole blood potency, were shown to inhibit LPS-induced TNFα in an in vivo murine model. To our knowledge, this is the first published in vivo demonstration that inhibition of the IRAK4 pathway by a small molecule can recapitulate the phenotype of IRAK4 knockout mice.
Collapse
Affiliation(s)
- L Nathan Tumey
- Pfizer Global R&D, 445 Eastern Point Rd., Groton, CT 06340, USA.
| | | | - Niala Bhagirath
- Pfizer Global R&D, 445 Eastern Point Rd., Groton, CT 06340, USA
| | - Jaechul Shim
- Pfizer Global R&D, 445 Eastern Point Rd., Groton, CT 06340, USA
| | | | - Deborah Goodwin
- Pfizer Global R&D, 200 Cambridge Park Dr., Cambridge, MA 02140, USA
| | - Eric M Bennett
- Pfizer Global R&D, 87 Cambridgepark Dr., Cambridge, MA 02140, USA
| | - Mengmeng Wang
- Pfizer Global R&D, 1 Burtt Rd., Andover, MA 01810, USA
| | - Lih-Ling Lin
- Pfizer Global R&D, 200 Cambridge Park Dr., Cambridge, MA 02140, USA
| | - Barry Press
- Pfizer Global R&D, 445 Eastern Point Rd., Groton, CT 06340, USA
| | - Marina Shen
- Pfizer Global R&D, 200 Cambridge Park Dr., Cambridge, MA 02140, USA
| | | | - Paul Morgan
- Pfizer Global R&D, 200 Cambridge Park Dr., Cambridge, MA 02140, USA
| | - Shashi Mohan
- Pfizer Global R&D, 200 Cambridge Park Dr., Cambridge, MA 02140, USA
| | - Julia Shin
- Pfizer Global R&D, 200 Cambridge Park Dr., Cambridge, MA 02140, USA
| | - Vikram R Rao
- Pfizer Global R&D, 200 Cambridge Park Dr., Cambridge, MA 02140, USA
| |
Collapse
|
29
|
Ma D, Zhang H, Jin F, Charati M, Khandke K, Lucas J, Follettie M, Tumey LN, Gerber HP, Tchistiakova L, Sapra P. Abstract 1241: Targeting the IL-13 receptor alpha 2 with novel antibody-drug conjugates for the treatment of cancer. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-1241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The IL-13 receptor alpha 2 (IL-13Rα2) is a transmembrane protein that is highly expressed on several cancers including glioblastoma, ovarian, pancreatic cancers. It can internalize after binding to its ligand IL-13 or in response to ligation with an antibody. In addition, we have discovered that IL-13Rα2 is up-regulated in tumor cell lines that are resistant to chemotherapeutic drugs. These properties make IL-13Rα2 an attractive target for antibody-drug conjugate (ADC), an emerging modality of molecularly targeted cancer therapies. A humanized monoclonal antibody, hAB08 with an affinity of 0.17 nM to the soluble recombined hIL-13Rα2, was conjugated with two novel microtubule inhibitors (MTIs), MTI1 and MTI2, developed by Pfizer. In vitro cytotoxicity of the conjugates was tested against IL-13Rα2 positive and negative cell lines. These conjugates were effective against the IL-13Rα2 positive cell lines (PC3MM2 and A375), having an IC50 ranging from 1.1 to 3.8 ng Ab/mL. However, both of the ADCs were not active against the IL-13Rα2 negative H460 cell line. When treating mice with established human PC3MM2 and A375 tumors, these conjugates were efficacious at 3 mg/kg in reducing tumor growth. In the PC3MM2 model, treatment with hAB08-MTI1 and hAB08-MTI2 resulted in 5 out of 8 or 3 out of 8 animals without measurable tumors at Day 76, respectively. In contrast, the vehicle control group and control ADC (hIgG8.8-MTI1 and hIgG8.8-MTI2) groups were terminated at Day 15, 15, 19 due to the large size of tumors, respectively. These in vitro and in vivo results demonstrate potent antitumor activities of hAB08-MTI1 and hAB08-MTI2 against IL-13Rα2 positive tumors. The findings support the development of novel hAB08-MTI1 or hAB08-MTI2 ADCs as a molecularly targeted therapy for cancer patients that are resistant to standard chemotherapy.
Citation Format: Dangshe Ma, Haige Zhang, Fang Jin, Manoj Charati, Kiran Khandke, Judy Lucas, Max Follettie, L. Nathan Tumey, Hans-Peter Gerber, Lioudmila Tchistiakova, Puja Sapra. Targeting the IL-13 receptor alpha 2 with novel antibody-drug conjugates for the treatment of cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1241. doi:10.1158/1538-7445.AM2013-1241
Collapse
|
30
|
Tumey LN, Robarge MJ, Gleason E, Song J, Murphy SM, Ekema G, Doucette C, Hanniford D, Palmer M, Pawlowski G, Danzig J, Loftus M, Hunady K, Sherf B, Mays RW, Stricker-Krongrad A, Brunden KR, Bennani YL, Harrington JJ. 3-Indolyl sultams as selective CRTh2 antagonists. Bioorg Med Chem Lett 2010; 20:3287-90. [DOI: 10.1016/j.bmcl.2010.04.046] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2010] [Revised: 04/08/2010] [Accepted: 04/12/2010] [Indexed: 10/19/2022]
|
31
|
Tumey LN, Bhagirath N, Brennan A, Brooijmans N, Lee J, Yang X, Boschelli DH. 5-Vinyl-3-pyridinecarbonitrile inhibitors of PKCθ: Optimization of enzymatic and functional activity. Bioorg Med Chem 2009; 17:7933-48. [DOI: 10.1016/j.bmc.2009.10.020] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2009] [Revised: 10/08/2009] [Accepted: 10/09/2009] [Indexed: 12/11/2022]
|
32
|
Nathan Tumey L, Boschelli DH, Lee J, Chaudhary D. 2-Alkenylthieno[2,3-b]pyridine-5-carbonitriles: Potent and selective inhibitors of PKCθ. Bioorg Med Chem Lett 2008; 18:4420-3. [PMID: 18606543 DOI: 10.1016/j.bmcl.2008.06.040] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2008] [Revised: 06/12/2008] [Accepted: 06/12/2008] [Indexed: 10/21/2022]
|
33
|
Mdluli KE, Witte PR, Kline T, Barb AW, Erwin AL, Mansfield BE, McClerren AL, Pirrung MC, Tumey LN, Warrener P, Raetz CRH, Stover CK. Molecular validation of LpxC as an antibacterial drug target in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50:2178-84. [PMID: 16723580 PMCID: PMC1479155 DOI: 10.1128/aac.00140-06] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
LpxC [UDP-3-O-(R-3-hydroxymyristoyl)-GlcNAc deacetylase] is a metalloamidase that catalyzes the first committed step in the biosynthesis of the lipid A component of lipopolysaccharide. A previous study (H. R. Onishi, B. A. Pelak, L. S. Gerckens, L. L. Silver, F. M. Kahan, M. H. Chen, A. A. Patchett, S. M. Galloway, S. A. Hyland, M. S. Anderson, and C. R. H. Raetz, Science 274:980-982, 1996) identified a series of synthetic LpxC-inhibitory molecules that were bactericidal for Escherichia coli. These molecules did not inhibit the growth of Pseudomonas aeruginosa and were therefore not developed further as antibacterial drugs. The inactivity of the LpxC inhibitors for P. aeruginosa raised the possibility that LpxC activity might not be essential for all gram-negative bacteria. By placing the lpxC gene of P. aeruginosa under tight control of an arabinose-inducible promoter, we demonstrated the essentiality of LpxC activity for P. aeruginosa. It was found that compound L-161,240, the most potent inhibitor from the previous study, was active against a P. aeruginosa construct in which the endogenous lpxC gene was inactivated and in which LpxC activity was supplied by the lpxC gene from E. coli. Conversely, an E. coli construct in which growth was dependent on the P. aeruginosa lpxC gene was resistant to the compound. The differential activities of L-161,240 against the two bacterial species are thus the result primarily of greater potency toward the E. coli enzyme rather than of differences in the intrinsic resistance of the bacteria toward antibacterial compounds due to permeability or efflux. These data validate P. aeruginosa LpxC as a target for novel antibiotic drugs and should help direct the design of inhibitors against clinically important gram-negative bacteria.
Collapse
Affiliation(s)
- Khisimuzi E Mdluli
- Department of Research Biology, Chiron Corporation, Seattle, WA 98119, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Tumey LN, Bom D, Huck B, Gleason E, Wang J, Silver D, Brunden K, Boozer S, Rundlett S, Sherf B, Murphy S, Dent T, Leventhal C, Bailey A, Harrington J, Bennani YL. The identification and optimization of a N-hydroxy urea series of flap endonuclease 1 inhibitors. Bioorg Med Chem Lett 2005; 15:277-81. [PMID: 15603939 DOI: 10.1016/j.bmcl.2004.10.086] [Citation(s) in RCA: 66] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2004] [Revised: 10/28/2004] [Accepted: 10/30/2004] [Indexed: 10/26/2022]
Abstract
Flap endonuclease-1 (FEN1) is a key enzyme involved in base excision repair (BER), a primary pathway utilized by mammalian cells to repair DNA damage. Sensitization to DNA damaging agents is a potential method for the improvement of the therapeutic window of traditional chemotherapeutics. In this paper, we describe the identification and SAR of a series of low nanomolar FEN1 inhibitors. Over 1000-fold specificity was achieved against a related endonuclease, xeroderma pigmentosum G (XPG). Two compounds from this series significantly potentiate the action of methyl methanesulfonate (MMS) and temozolamide in a bladder cancer cell line (T24). To our knowledge, these are the most potent endonuclease inhibitors reported to date.
Collapse
Affiliation(s)
- L Nathan Tumey
- Athersys, Inc., 3201 Carnegie Ave., Cleveland, OH 44115, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Tumey LN, Huck B, Gleason E, Wang J, Silver D, Brunden K, Boozer S, Rundlett S, Sherf B, Murphy S, Bailey A, Dent T, Leventhal C, Harrington J, Bennani YL. The identification and optimization of 2,4-diketobutyric acids as flap endonuclease 1 inhibitors. Bioorg Med Chem Lett 2005; 14:4915-8. [PMID: 15341951 DOI: 10.1016/j.bmcl.2004.07.028] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2004] [Revised: 07/13/2004] [Accepted: 07/14/2004] [Indexed: 10/26/2022]
Abstract
There have been several recent reports of chemopotentiation via inhibition of DNA repair processes. Flap endonuclease 1 (FEN1) is a key enzyme involved in base excision repair (BER), a primary pathway utilized by mammalian cells to repair DNA damage. In this report, we describe the identification and SAR of a series of 2,4-diketobutyric acid FEN1 inhibitors.
Collapse
Affiliation(s)
- L Nathan Tumey
- Athersys, Inc., 3201 Carnegie Ave., Cleveland, OH 44115, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Robarge MJ, Bom DC, Tumey LN, Varga N, Gleason E, Silver D, Song J, Murphy SM, Ekema G, Doucette C, Hanniford D, Palmer M, Pawlowski G, Danzig J, Loftus M, Hunady K, Sherf BA, Mays RW, Stricker-Krongrad A, Brunden KR, Harrington JJ, Bennani YL. Isosteric ramatroban analogs: selective and potent CRTH-2 antagonists. Bioorg Med Chem Lett 2005; 15:1749-53. [PMID: 15745833 DOI: 10.1016/j.bmcl.2004.12.055] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2004] [Revised: 12/17/2004] [Accepted: 12/20/2004] [Indexed: 11/16/2022]
Abstract
The chemoattractant receptor-homologous molecule expressed on T(H)2 cells (CRTH-2), also found on eosinophils and basophils, is a prostaglandin D2 receptor involved in the recruitment of these cell types during an inflammatory response. In this report, we describe the synthesis and optimization of a ramatroban isostere that is a selective and potent antagonist of CRTH-2 which may be useful in the treatment of certain diseases.
Collapse
Affiliation(s)
- Michael J Robarge
- Athersys, Inc., Medicinal Chemistry, 3201 Carnegie Avenue, Cleveland, OH 44115-2634, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Pirrung MC, Tumey LN, McClerren AL, Raetz CRH. High-throughput catch-and-release synthesis of oxazoline hydroxamates. Structure-activity relationships in novel inhibitors of Escherichia coli LpxC: in vitro enzyme inhibition and antibacterial properties. J Am Chem Soc 2003; 125:1575-86. [PMID: 12568618 DOI: 10.1021/ja0209114] [Citation(s) in RCA: 78] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
LpxC is a zinc amidase that catalyses the second step of lipid A biosynthesis in Gram-negative bacteria. Oxazolines incorporating a hydroxamic acid, which is believed to coordinate to the single essential zinc ion, at the 4-position are known inhibitors of this enzyme. Some of these enzyme inhibitors exhibit antibacterial activity through their inhibition of LpxC. We recently developed a method for the synthesis of oxazolines using resin capture and ring-forming release that eliminates traditional purification steps and can be used in high-throughput synthesis. Using our method, oxazoline hydroxamates with diverse 2-substituents were prepared in library form as candidate inhibitors for LpxC. Two conventional methods for oxazoline synthesis were also applied to generate more than 70 compounds. The groups at the 2-position included a wide variety of substituted aromatic rings and a limited selection of alkyl groups. These compounds were screened against wild-type and LpxC inhibitor-sensitive strains of Escherichia coli, as well as wild-type Pseudomonas aeruginosa. Inhibition of the E. coli LpxC enzyme was also investigated. A broad correlation between enzyme inhibitory and antibacterial activity was observed, and novel compounds were discovered that exhibit antibacterial activity but fall outside earlier-known structural classes.
Collapse
Affiliation(s)
- Michael C Pirrung
- Department of Chemistry, Levine Science Research Center, Box 90317, Duke University, Durham, North Carolina 27708-0317, USA.
| | | | | | | |
Collapse
|
38
|
Pirrung MC, Tumey LN, Raetz CRH, Jackman JE, Snehalatha K, McClerren AL, Fierke CA, Gantt SL, Rusche KM. Inhibition of the antibacterial target UDP-(3-O-acyl)-N-acetylglucosamine deacetylase (LpxC): isoxazoline zinc amidase inhibitors bearing diverse metal binding groups. J Med Chem 2002; 45:4359-70. [PMID: 12213077 DOI: 10.1021/jm020183v] [Citation(s) in RCA: 85] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
UDP-3-O-[R-3-hydroxymyristoyl]-GlcNAc deacetylase (LpxC) is a zinc amidase that catalyzes the second step of lipid A biosynthesis in Gram negative bacteria. Known inhibitors of this enzyme are oxazolines incorporating a hydroxamic acid at the 4-position, which is believed to coordinate to the single essential zinc ion. A new structural class of inhibitors was designed to incorporate a more stable and more synthetically versatile isoxazoline core. The synthetic versatility of the isoxazoline allowed for a broad study of metal binding groups. Nine of 17 isoxazolines, each incorporating a different potential metal binding functional group, were found to exhibit enzyme inhibitory activity, including one that is more active than the corresponding hydroxamic acid. Additionally, a designed affinity label inhibits LpxC in a time-dependent manner.
Collapse
Affiliation(s)
- Michael C Pirrung
- Department of Chemistry, Levine Science Research Center, Box 90317, Duke University, Durham, NC 27708-0317, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Abstract
A (19)F NMR method for encoding of combinatorial libraries has been developed. Aryl fluorides whose chemical shifts are modified by aromatic substituents were prepared and attached to resin support beads that were used in the split-pool synthesis of peptoids. The detection of the (19)F NMR signal of tags derived from a single "big bead" was demonstrated. The library diversity arises from peptoid amines and the cyclic anhydrides used in their acylation. The resulting 90-compound library was examined for metal ion binding, and novel ligands for iron and copper were discovered. Their binding constants were determined to be in the low micromolar range using conventional methods. The library was also examined for autocatalysis of acylation, and a molecule possessing the catalytic triad of serine proteases was deduced.
Collapse
Affiliation(s)
- Michael C Pirrung
- Department of Chemistry, Levine Science Research Center, Box 90317, Duke University, Durham, North Carolina 27708-0317, USA
| | | | | |
Collapse
|
40
|
Abstract
Polymer-bound tosyl chloride was used to capture hydroxyamides (prepared from amino alcohols and acid chlorides) from the reaction mixtures in which they were formed. The resulting support-bound amide/ sulfonates undergo ring-forming cleavage from the polymer on treatment with weak base, forming oxazolines and oxazines in generally good yield and high purity. Low temperature is required in the polymer-loading step to slow the cleavage process and achieve high efficiency in the execution of the method.
Collapse
Affiliation(s)
- M C Pirrung
- Department of Chemistry, Levine Science Research Center, Duke University, Durham North Carolina 27708-0317, USA
| | | |
Collapse
|
41
|
Jackman JE, Fierke CA, Tumey LN, Pirrung M, Uchiyama T, Tahir SH, Hindsgaul O, Raetz CR. Antibacterial agents that target lipid A biosynthesis in gram-negative bacteria. Inhibition of diverse UDP-3-O-(r-3-hydroxymyristoyl)-n-acetylglucosamine deacetylases by substrate analogs containing zinc binding motifs. J Biol Chem 2000; 275:11002-9. [PMID: 10753902 DOI: 10.1074/jbc.275.15.11002] [Citation(s) in RCA: 149] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) catalyzes the second step in the biosynthesis of lipid A, a unique amphiphilic molecule found in the outer membranes of virtually all Gram-negative bacteria. Since lipid A biosynthesis is required for bacterial growth, inhibitors of LpxC have potential utility as antibiotics. The enzymes of lipid A biosynthesis, including LpxC, are encoded by single copy genes in all sequenced Gram-negative genomes. We have now cloned, overexpressed, and purified LpxC from the hyperthermophile Aquifex aeolicus. This heat-stable LpxC variant (the most divergent of all known LpxCs) displays 32% identity and 51% similarity over 277 amino acid residues out of the 305 in Escherichia coli LpxC. Although A. aeolicus LpxC deacetylates the substrate UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine at a rate comparable with E. coli LpxC, a phenyloxazoline-based hydroxamate that inhibits E. coli LpxC with K(i) of approximately 50 nM (Onishi, H. R., Pelak, B. A., Gerckens, L. S., Silver, L. L., Kahan, F. M., Chen, M. H., Patchett, A. A., Galloway, S. M., Hyland, S. A., Anderson, M. S., and Raetz, C. R. H. (1996) Science 274, 980-982) does not inhibit A. aeolicus LpxC. To determine whether or not broad-spectrum deacetylase inhibitors can be found, we have designed a new class of hydroxamate-containing inhibitors of LpxC, starting with the structure of the physiological substrate. Several of these compounds inhibit both E. coli and A. aeolicus LpxC at similar concentrations. We have also identified a phosphinate-containing substrate analog that inhibits both E. coli and A. aeolicus LpxC, suggesting that the LpxC reaction proceeds by a mechanism similar to that described for other zinc metalloamidases, like carboxypeptidase A and thermolysin. The differences between the phenyloxazoline and the substrate-based LpxC inhibitors might be exploited for developing novel antibiotics targeted either against some or all Gram-negative strains. We suggest that LpxC inhibitors with antibacterial activity be termed "deacetylins."
Collapse
Affiliation(s)
- J E Jackman
- Department of Biochemistry, Duke University Medical Center, Durham, North Carolina 27710, USA
| | | | | | | | | | | | | | | |
Collapse
|